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Abstract
In this review we summarize our recent efforts in trying to understand
the role of heterogeneity in cancer progression by using neural networks to
characterise different aspects of the mapping from a cancer cells genotype
and environment to its phenotype. Our central premise is that cancer is
an evolving system subject to mutation and selection, and the primary
conduit for these processes to occur is the cancer cell whose behaviour is
regulated on multiple biological scales. The selection pressure is mainly
driven by the microenvironment that the tumour is growing in and this
acts directly upon the cell phenotype. In turn, the phenotype is driven by
the intracellular pathways that are regulated by the genotype. Integrat-
ing all of these processes is a massive undertaking and requires bridging
many biological scales (i.e. genotype, pathway, phenotype and environ-
ment) that we will only scratch the surface of in this review. We will
focus on models that use neural networks as a means of connecting these
different biological scales, since they allow us to easily create heterogene-
ity for selection to act upon and importantly this heterogeneity can be
implemented at different biological scales. More specifically, we consider
three different neural networks that bridge different aspects of these scales
and the dialogue with the micro-environment, (i) the impact of the micro-
environment on evolutionary dynamics, (ii) the mapping from genotype
to phenotype under drug-induced perturbations and (iii) pathway activ-
ity in both normal and cancer cells under different micro-environmental
conditions.
Introduction
There has been a great deal of effort focused on trying to define molecular
signatures of many different aspects of cancer (including risk, progression and
treatment response) with limited success. This lack of success is largely due to
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the multiscale aspect of cancer (1), and was recently brought into sharp focus
with the landmark publication by Swanton and colleagues (2) in which they
showed that a single tumour can contain multiple distinct genetic signatures.
This so called, intratumour heterogeneity, is at the heart of our lack of success
with such biomarkers and emphasizes a need for a deeper understanding of how
genetic changes alter intracellular signalling and how this signalling alters the
cellular phenotype. To complicate matters further, all of this intrinsic hetero-
geneity does not happen in a vacuum nor does it appear instantaneously, rather
it occurs in a temporally dynamic spatially heterogeneous micro-environment
that directly impacts tumour heterogeneity.
Another critical aspect of this heterogeneity is the role that it plays in ther-
apuetic escape. The recent advent of targeted therapies, where drugs are em-
ployed to target specific genetic mutants, whilst appearing as initially a huge
success for cancer control, have also been hampered by heterogeneity and given
way to drug resistance (see (3) for a review). Drug resistance, in general, is a
major problem in cancer treatment and therefore understanding how this resis-
tance develops and can be slowed or even prevented is a current major focus
of the cancer community (see (4) for a review). A recent strategy to deal with
this resistance is to utilize combination therapies, that combine targeted drugs
with more broad base chemotherapuetic agents (see (5) for a review) and has
achieved mixed results. What is becoming clear is that a deeper understanding
of how selection (via drugs or otherwise) alters heterogeneity at the phenotypic
scale and differentially at the geneotypic scale, will allow us to develop smarter
more effective therapies with already available drugs.
In the last decades the network paradigm has become ubiquitous in cancer
biology (6), and the idea that a biological system can be viewed as a con-
glomeration of discrete units that interact with a limited set of neighbouring
units, has been applied on all scales of the disease, ranging from the regulation
of RNA-molecules (7), the dynamics of intra-cellular signalling pathways (8),
the interactions of different cell types within a tumour (9), to the insight that
metastatic spread occurs on a network defined by the circulatory system (10).
Network dynamics often run counter to linear and uni-directional reasoning,
and hinder our understanding of the relation between mutations and pheno-
typic change. Such nonlinear and counter-intuitive effects are known to arise
already on the scale of intra-cellular signalling, where the inhibition of signalling
molecules often has unexpected effects on signal transduction (11), but the con-
sequences are even greater when the micro-environment and tumour evolution
are taken into account. Since evolution selects phenotypes, not genotypes, tu-
mours often consist of many distinct genotypes with similar phenotypes. The
environment provides the key context upon which this evolutionary game is
played out, but it is not a static environment. There is a direct feedback be-
tween the environment and successful phenotypes simply because these pheno-
types can actively alter the microenvironment leading to changes in the selection
pressure – ultimately pushing the tumor along the path of progression.
Understanding the relationship between signalling, the micro-environment
and tumour evolution is required if we are to understand and rationally de-
sign effective anti-cancer therapies. In fact, even describing the unperturbed
mapping from genotype to cellular phenotype is far beyond our current state
of understanding. In a majority of cases our intuition is insufficient to grasp
the many levels of simultaneous interactions occuring in a growing tumour, and
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hence it seems as if mathematical modelling with its ability to describe feedback
and non-linearities as well as incorporate these dynamics on different scales, is
the only way forward (12).
In this review we will discuss some recent mathematical modelling that has
taken a few formative first steps in trying to understand this dynamic multiscale
feedback system. We will focus specifically on individual-based models that use
neural networks as a means of connecting these different biological scales of
tumour growth.
Neural networks in cancer modelling
Two different flavours of individual-based models of tumour growth have served
as sources of inspiration for our neural network approach: evolutionary models
in which a collection of static phenotypes grow and compete, and models with
elaborate intra-cellular signalling, but without an evolutionary component. The
former, exemplified by Anderson’s (13) investigation of the impact of oxygen
concentration and extra-cellular matrix density on tumour evolution, provided
the backbone for modelling evolutionary dynamics, while models from the latter
category, such as the work of Zhang et al. (14), which investigated the role of
EGFR-signalling on proliferation and migration, provided the inspiration for
mapping micro-environment to cellular phenotype.
The coalescence of these approaches in cancer modelling: selection and evo-
lution of fixed phenotypes, and phenotypes that depend in a non-trivial way on
environment and genotype, can be realised by letting the behaviour of each cell
be determined by a neural network whose output – the phenotype – depends
on the environment, genotype and pathway activity. In this capacity, neural
networks serve as models of both the current state of cancer cell pathway ac-
tivity (and hence phenotype) and changes due to mutation and selection. They
also allow us to easily create heterogeneity for selection to act upon and impor-
tantly this heterogeneity can be implemented at different biological scales (i.e.
genotype, pathway, phenotype or environment). We will describe three models
that focus on different aspects of this mapping (see fig. 1): (i) the impact of
the micro-environment on phenotypic evolutionary dynamics, (ii) the mapping
from genotype to phenotype under drug-induced perturbations and (iii) path-
way activity in both normal and cancer cells under different micro-environmental
conditions.
1. The impact of the micro-environment on tu-
mour evolution
Artificial neural networks have traditionally been used for machine-learning
tasks such as classification and prediction, some examples being the detection
of heart abnormalities (15), finger-print recognition (16) and breast cancer pre-
diction (17). In these settings the network is trained for detection with a data
set that consists of a number of variables from each sample together with the
outcome. There are two approaches to solve this problem, either by using a
single network that is optimised with respect to the training set using an error
minimising algorithm like back-propagation (18) or by using an evolutionary al-
gorithm (19). Another application, more in line with the use in individual-based
3
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Figure 1: Colour coded summary of the different scales that each modelling ap-
proaches considers in this review. Coloured arrows emphasize where approaches
overlap and where they are distinct.
models, is the implementation of neural networks in evolving robot controllers
(20). Here the input to the network are sensors of the robot (e.g. proximity
sensors) and the output of the network controls the motors.
The use of neural networks as a means to map the micro-environment to
tumour cell phenotypes within a multi-cellular context was pioneered by Gerlee
& Anderson in a series of papers that investigated the impact of the micro-
environment on tumour growth and evolution (21, 22, 23, 24).
The approach had been hinted at by Bray (25), stating that ”...systems of
interacting proteins act as neural networks trained by evolution to respond appro-
priately to patterns of extracellular stimuli” (26), and it was subsequently used
in a single-cell context by Vohradsky as a means to model the λ-bacteriophage
lysis/lysogeny decision circuit (27). In the context of cancer, a more data-
driven application was developed by Naranyan et al., who used neural networks
to model temporal micro-array data (28). In a similar vein Nelander et al. (29)
used a feed-forward neural network to model the pathway activity in a breast
cancer cell line under combinatorial drug perturbation experiments.
Importantly these efforts were focused on the dynamics of a single cell, and
the contribution of Gerlee & Anderson was to incorporate this framework into
an individual-based dynamic model, that allowed for mutation and hence evo-
lution of the mapping from environment to phenotype to occur in a spatially
meaningful manner.
This approach has also found other applications in cancer modelling, e.g.
as a means to model the evolutionary dynamics during drug treatment (30).
In that study, the dynamics of the model were shown to agree with in vitro
experiments, and also suggested novel mechanisms of action of the drug Maspin.
The methodology has also been used for modelling the growth dynamics of
multi-cellular spheroids in the presence of bioreductive drugs (31). That study
focused on the problem of drug penetration and it was shown that the model
could account for the growth rate, morphology and drug distribution seen in
experiments.
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Figure 2: The structure of the response network. Environmental variables
(green) are presented to the input-layer and then fed through the pathways
(red) where a phenotype is calculated (grey). Connections between these layers
represent the mappings from receptors to pathways (W) and from pathways to
phenotype (V).
The environment-phenotype network
The underlying idea behind the framework is the observation that the envi-
ronment together with the signalling pathways of the cell jointly determines
the behaviour or phenotype of a cell. Or from a more mechanistic viewpoint,
that environmental stimuli fed through the signalling network determined by
the genotype gives rise to the phenotype. This provides the motivation for us-
ing feed-forward neural networks, that have a directional and layered structure,
consisting of an input, hidden and output layer of nodes (see fig. 2).
The output of the network is determined by feeding the micro-environmental
variables to the input layer of the network and sequentially updating first the
hidden layer and then the output layer. The output of the network dictates the
phenotype of the cell and is deterministic, being dependent on the weight ma-
trices (W and V) and the environmental input (for details we refer to previous
publications (21, 24)).
In order to capture the evolutionary dynamics of tumour growth this model
includes mutations to the weight matrices. The mutations alter the connection
strength between the nodes, which in turn changes how the cells respond to the
micro-environment. By embedding these networks in individual cells and allow-
ing them to mutate as they divide, we can create a caricature of an evolving tu-
mour that responds to and modifies its micro-environment in a spatio-temporal
manner. We achieved this by utilising a hybrid cellular automaton framework
in which each cells behaviour is driven by the neural network.
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Hybrid model
The hybrid model uses a cellular automata based approach that considers cells
as simple points on a grid, that also contains continuous concentration fields of
micro-environment factors, and together represent a thin slice of tissue. Each
cell contains a feed-forward neural network that links environment to phenotype.
The initial matrices were parametrised in such a way that the behaviour of
the cells would resemble that of early stage neoplastic cells (see Appendix for
details). The grid itself represents the micro-environment and can contain any
number of possible variables, however, for simplicity we focus on the case where
the concentration of oxygen is the only micro-environmental factor considered.
The dynamics of the oxygen concentration in space and time are controlled by,
a discretised version of, the following partial differential equation
∂c(~x, t)
∂t
= Dc∇2c(~x, t)− fc(~x, t), (1)
where Dc is the diffusion constant of oxygen and fc(~x, t) gives the individual
cell oxygen consumption rate for the cell at position ~x and time t. We make
use of a fixed boundary condition to simulate a situation where the domain is
surrounded by vessels.
In this hybrid model, cells perform three basic functions: proliferation, qui-
escence, and apoptosis (the phenotypic traits). The neural network within the
cells controls these functions. The environmental variables (oxygen concentra-
tion and cell crowding, i.e. available space on the grid) are considered as input
to the network. Please note that the node connections can vary and evolve from
cell to cell, because of mutations that occur during cell division. The input is
therefore processed by the cells’ individual networks in slightly different ways.
For instance, a low value of oxygen concentration may trigger apoptosis in one
cell, but not another, because their respective networks have evolved apart.
Similar effects occur for quiescence and proliferation. Therefore, the model cap-
tures a crucial component of cancer progression, the generation of phenotypic
variation within a population of growing cancer cells and how the selection im-
posed by different environmental conditions acts on this variation. More details
on the precise implementation of this hybrid cellular automata model can be
found in (32, 23).
The impact of oxygen on tumour growth and evolution
The oxygen levels in a tissue are known to be a key regulator of tumour growth
and progression, as it can both facilitate and inhibit the tumour in counter
intuitive ways. We have previously used our neural network driven modelling
paradigm to investigate the impact of varying oxygenation concentration on
tumour growth and evolution (32, 23) and summarise some key results below.
Figure 3 shows a simulated tumour in different stages of growth at t = 20, 60
and 100 days for two different values of the background oxygen concentration as
well as the oxygen distribution at each time point for the low oxygen case. This
figure clearly shows that a limited oxygen supply significantly influences the
growth dynamics and morphology of the tumour. In the high oxygen case the
tumour only consists of proliferating (red) and quiescent (green) cells growing
with a more compact and rounded morphology, while in the low oxygen case
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Figure 3: The two upper rows show the spatial distribution of cells at t =20,
60 and 100 days. Proliferating cells are coloured red, quiescent green and dead
cells are blue. We can see a clear difference in the morphology of the tumours in
the low and high oxygen case. The lower row shows the oxygen concentration
in the low oxygen case.
the tumour consists mostly of dead cells (blue) with proliferating cells at the tip
of a more skeletal fingered structure. This structure is induced by competition
for the limited oxygen, displayed in the lower panel and shows that a gradient
of oxygen appears early in the simulation (t=20). The limited supply of oxygen
means that the oxygen level rapidly drops below the apoptotic threshold in the
centre of the tumour, which leads to the development of a necrotic core and
subsequent invasive fingers.
In this modelling framework, the phenotype of a cell is a function of its im-
mediate micro-environment (oxygen concentration and local cell density), and
therefore context dependent. In order to quantify the evolutionary change,
the average phenotype was calculated as the proportion of the two-dimensional
input space (oxygen concentration and number of neighbouring cells) that corre-
sponds to each phenotypic response (proliferation, quiescence, apoptosis). This
measure is summarised in a 3-dimensional vector S, that was termed the aver-
age phenotype or response vector, which reflects the behaviour of the cell. The
initial phenotype, used as a seed in the simulation, had a measure of S = (0.67,
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Figure 4: The time evolution of the average phenotypes in the population for the
high and low oxygen case. The most abundant phenotypes have been highlighted
and their response vectors are displayed. The fluctuations observed in the low
oxygen case are a result of the smaller population size.
0.18, 0.15), which means that 67 % of the input space corresponds to prolifera-
tion, 18 % to quiescence and 15 % to apoptosis (see figure 13 in the Appendix
for the actual network used).
This measure was used to analyse the evolution of phenotypes in the popu-
lation by tracking the abundance of the average phenotypes in the population.
Note that this is different from measuring the abundance of different subclones
in the population as two subclones with distinct networks may still give rise
to the same average phenotype. The time evolution of the phenotypes was
measured for both oxygen cases and is shown in figure 4, where each line corre-
sponds to a unique average phenotype and the most significant phenotypes have
been highlighted. In the high oxygen environment we observe a steady decline
of the initial phenotype and the emergence of several new phenotypes all with
low abundances. This is in contrast with the dynamics in the low oxygen case
where the initial phenotype decreases more rapidly and the population becomes
dominated by a single phenotype.
Similar results, both in terms of the impact of the microenvironment on
the morphology and on the evolutionary dynamics, have been observed with
other models. For example Anderson et al.(33) have shown that a harsh mi-
croenvironment (in terms of high extra-cellular matrix density and low oxygen
concentration) gives rise the selection of a single subclone with aggressive traits.
That model also recapitulates the fingered morphology, which has also been seen
in a number of other types of models, e.g. level-set models (34), hybrid cellular
automata (35) and cellular potts models (36).
The phenotypic diversity is only one part of the story, as it represents the
output of the neural network for each cell in the context of a given environment.
Another important aspect of this result, is how the mappings changed as result
of mutation and selection, i.e. how did the network connectivity of the cancer
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cells change? If we consider the overall connectivity of a subclone to represent
its genotype, then we were able to show that the genotypic diversity was higher
in the low compared to high oxygen case (21), suggesting that harsh selective
growth conditions might give rise to evolutionary dynamics where the pheno-
types in the population converge, while the genotypes diverge. This insight was
only made possible through the use of a mutable mapping from environment
and genotype to the phenotype. Clearly this is a gross simplification of the
relationship between genotype and phenotype and we endeavour to refine this
in the following section.
2. The emergence of resistance in a multi-drug
context
Understanding how the phenotype of a cell emerges from its genotype is, even in
the absence of complicating environmental stimuli, a challenging problem, and
even a partial understanding of this process could be helpful when designing
anti-cancer therapies. This is particularly relevant now that targeted drugs, that
inhibit specific genes or proteins, are becoming the standard of care for many
types of cancer (37). If two targeted drugs are administered in combination,
how do their effects on intra-cellular signalling interact, and equally important,
how do they influence the evolution of resistance? Is the efficacy higher when
the drugs are administered in parallel or in sequence, and in which case is the
risk of resistance minimised?
The answers naturally depend on the architecture of the signalling network
and the location of the targeted genes within that network. However, it is
possible that some general principles exist, and we will give an example here of
how neural networks can be used to tackle this problem.
The genotype-phenotype map
Again we utilize neural networks to model the intra-cellular dynamics, but here
we have focused on the effect of the genotype on intra-cellular signalling and
disregard any environmental influence (see fig. 1). Instead of viewing the geno-
type implicitly, as the weights and connections in the network, we now explicitly
model it by letting the input nodes represent the mutational status of a subset
of genes, that contribute to pathway activity, which then drive the phenotype
p of the cell. The application of a specific drug can then be modelled by modi-
fications on different levels in the network, e.g. by removing the link between a
gene and a pathway it contributes to.
We model the influence of each gene on the phenotype of a subclone using a
feed-forward neural network (see fig. 5), and specify the fitness or growth rate
of a subclone i as a function of the phenotype Fi = F (pi), where we assume
that an intermediate phenotype fitness optimal and define
F (p) = e−(p−0.5)
2/σ (2)
where σ = 0.1 determines the width of the fitness peak.
In this context we interpret the network weights as corresponding to a specific
signalling network (or type of cancer), and investigate the typical properties of
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such networks with the goal of learning something about how perturbations
propagate and interact in genotype-phenotype (GP)-maps.
genes, gi ∊ {0,1}
pathway activity, yi ∊[-1,1]
phenotype p ∊[-1,1]
 Wij
 Vi
Figure 5: Schematic of the genotype-phenotype map. In the model a number
of genes contribute additively to distinct pathways that in turn influence the
phenotype of the cell. Mutations at the genetic level, that activate/deactivate
genes, propagate through the network and alter the phenotype.
rThe GP-map, and specifically the set of subclones that have a high fitness,
depends on the weight matrices (W and V). In this general framework they
remain unspecified, but it is still possible to investigate the typical behaviour
of the model by analysing the average behaviour across many network realisa-
tions. In figure 6 we have made use of this technique to quantify the number of
genotypes that map to maximal fitness (F ≈ 1). This quantity was estimated
by creating 100 GP-maps, where the elements of W and V were chosen at ran-
dom from a uniform distribution in the interval [−1, 1], and for each network
realisation counting the number of genotypes for which |F − 1| < 10−2. From
this figure it is clear that the number of genotypes increases exponentially with
the number of genes in the network, and shows that even for small n there are
many genotypes that have a similair phenotype. This implies that although the
fitness landscape (as a function of phenotype) is single-peaked we can still have
many distinct genotypes with high fitness (38).
Population dynamics
To capture the growth of a tumour made up of a heterogeneous set of subclones
and how it responds to the application of drugs, we couple the GP-map to a
population dynamics model.
In the spirit of Beckman et al. (39), who also investigated the impact of het-
erogeneity on different therapies, we assume that tumour growth is unbounded
and that tumour heterogeneity is due to differential drug response among differ-
ent subclones. This is of course a gross simplification, but allows us to focus on
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Figure 6: The number of genotypes that map to F ≈ 1 as a function of the
number of genes in the network. The different curves correspond to varying the
number of pathways (hidden nodes) in the network. Results are averaged over
100 realisations.
the relevant aspects of clonal evolution and the acquisition of resistance. The
GP-map described above defines the growth rate of each subclone based on its
genotype, and we further assume that mutations occur at a rate µ during cell
division. Each subclone can be represented using a bit string of length n, e.g.
G = (011010), where each binary number corresponds the mutational status,
gi, of each gene considered. In terms of mutations we restrict ourselves to one
step mutants, which means that the possible mutants produced by a subclone
all lie at Hamming distance one from that subclone (i.e. they only differ by one
mutation). For generality we allow for back mutations to occur (i.e. 1 → 0),
despite the fact that they represent an unlikely biological event.
Since cell numbers in a tumour typically are very large we model this system
using ordinary differential equations and formulate the following equation for
the subclone abundances Ni (where i is the decimal equivalent of the binary
genotype):
dNi
dt
=
α 2n∑
j=1
QjiFjNj − δNi
 I(Ni) (3)
where α = log 2 is the maximal growth rate and 0 < Fj < 1 is the relative growth
rate of genotype j. Qij is the rate at which subclone i produces offspring of type
j, δ = 10−2 is a death rate constant across all clones, and I(·) is an indicator
11
function defined as
I(x) =
{
1 : x ≥ 1
0 : x < 1
which guarantees that fractional cell numbers do not contribute to cell division.
The sum across all subclones might seem counter-intuitive, but please note that
Qij = µ = 10
−6 only if i and j are neighbours in genotype space, Qii = 1− nµ
(the net growth rate adjusted for mutant daugther cells lost to other subclones),
and that all other entries are zero. Given the clonal origin of cancer we initiate
the model with a single subclone that is one mutational step away from the
wildtype (G = (0000...)).
Application of therapy
Within the model we can implement anti-cancer therapy by considering pertur-
bations to the GP-map at three distinct levels:
1. the inhibition of a single mutant protein i, which is achieved by setting
gi = 0 (reverting to wildtype) in all subclones, or equivalently by removing
all links from gene i, i.e. setting Wij = 0 for all j
2. inhibition of a single pathway j, which is achieved by setting yj = 0 in all
subclones
3. application of chemotherapy which is implemented by setting the fitness of
all subclones k with Fk > θ to zero, affecting those sublcones that divide
at a high rate.
For the two former therapies we also need to specify which gene/pathway to
target. This choice will be informed by a virtual biopsy, and we assume the
following simple protocol: target a gene that is mutated in the most dominant
clone. And for the pathway-level: target the pathway which has the highest
average activity in the population. The tumour is considered detected and
hence the treatment starts when M =
∑
iNi > 10
9. For all three therapies we
assume that the therapy lasts until the patient dies of excessive tumour burden,
which we assume to be M = 1013.
Preliminary results
Instead of focusing on a specific GP-map (i.e. a specific choice of W and V)
corresponding to a type of cancer (with its specific driver genes and pathways)
we investigate the general features of the model and the impact of the thera-
pies described above. We therefore simulate the model for a large number of
randomly generated genotype-phenotype maps, where each realisation of can be
viewed as a virtual patient with its unique disease state. Figure 7 shows the
three different therapies applied independently to the same patient, and clearly
emphasizes that they have differing impact on the evolutionary dynamics of the
tumour. The gene targeted therapy (a) affects all subclones and results in a
good response, while the pathway targeted therapy (b) and chemotherapy (c)
misses one or more subclones which leads to disease recurrence.
The effect of the different therapies on a population level can be seen in figure
8, which shows the outcome of each therapy in terms of Kaplan-Meier survival
12
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Figure 7: Subclone dynamics under (a) gene targeted therapy (b) pathway
therapy and (c) chemotherapy. This clearly illustrates that a single virtual
patient responds differently to the three therapies.
curves generated from a cohort of 100 virtual patients. For comparison this
plot also contains the untreated case as control (magenta). It is interesting to
note that gene-targeted therapy achieves almost the same long-term survival as
chemotherapy, but that on shorter time-scales chemotherapy has better survival
(the median survival is approximately 50 days for gene therapy, while roughly
100 days for chemotherapy). However, it should be noted that in reality the
toxicity of chemotherapeutic drugs is considerably higher than that of targeted
therapy, and that the chemotherapy therefore most likely cannot be applied to
the extent we have modelled here.
These preliminary results hint at the potential for this approach in being
able to test (and suggest) novel therapeutic strategies not only in terms of
mono-therapies but also in terms of combinations of these very different drug
treatments. However, the generality of this approach means we are not explicitly
considering a known network, making connecting these results to real drugs
difficult. In the next section we address this issue by explicitly considering a
subset of the kinase pathways.
3. Pathway activity in normal and cancer cells
In the previous sections the networks we have discussed were feedforward with no
direct feedback within each layer (or scale). Whilst a useful simpifying assump-
tion, this approach does not capture the reality that genes can and do regulate
other genes and likewise for proteins. We now therefore describe a recurrent
neural network (RNN) model that explicitly allows for regulatory feedback be-
tween genes. In RNNs, connections between nodes (genes or proteins) form a
directed cycle and therefore can have very different dynamics from the standard
feedforward networks. This approach has recently been used to infer genetic
networks (40, 41). Here, we will use a similar, yet more refined, approach to
study key signaling pathways in melanoma (skin cancer).
In melanoma cells, tightly regulated signaling networks (fig. 9) are signif-
icantly altered, leading to uncontrolled melanoma cell proliferation, survival
and migration. Of all the signaling pathways, mitogen-activated protein kinase
(MAPK) pathways and the PI3K/AKT pathway are considered key players in
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Figure 8: Kaplan-Meier survival curves for a virtual patient cohort of 100 pa-
tients on which the different therapies were applied. Therapy is applied when
the tumour has reached M = 109 cells and the patient is assumed to have
died when the tumour reaches a size of M = 1013. All three therapies improve
survival compared to the no-therapy control (blue curve).
the regulation of melanoma cell growth and death (see review by Smalley (42)).
We therefore use our RNN model to describe the MAPK and AKT/PI3K path-
ways and examine pathway responses and resulting cell phenotypes under dif-
ferent micro-environments (various concentrations of both, growth factors and
death signals). We first study the signaling of normal melanocytes and then
subsequently evolve this normal network under different micro-environmental
constraints to derive a melanoma-signaling pathway.
By constraining the network to specific pathways we can utilize it in many
different applications. The most obvious example being to investigate targeted
therapies, since these therapies typically target one of the molecules of the
MAPK or PI3K/AKT pathways. More specifically, the small molecule BRAF
kinase inhibitors have been used for the melanoma patients who harbor the ac-
tivating BRAF mutation (43, 44, 45, 46) to block the activity of BRAF in the
MAPK pathway. Using the model to better understand the signaling response
and phenotype of melanoma cells under this therapy will allow us to investigate
the underlying mechanisms of drug resistance. The model can also be inte-
grated into multicellular tumor modeling (for example, our vSkin model (47))
to investigate the role of signaling perturbations and heterogeneous expression
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of proteins on melanoma initiation, progression and treatment responses.
Figure 9: Complex signaling network. A network view generated by the string
database (http://string-db.org/) that summarizes the network of predicted as-
sociations for key proteins in the MAPK & AKT/PI3K pathways. The network
nodes are proteins, and the edges represent the predicted functional associa-
tions. The colored edges represent function; green-activation, red-inhibition,
blue-binding, pink-post-translation, black-reaction, yellow-expression and gray
(white)-homology.
Pathway Model
Due to computational feasibility, we will only consider a subset of proteins
(RAS, RAF, ERK, Growth inhibitor, BAD, AKT/PI3K, and PTEN) from the
network (fig. 9) and generate a far simpler network (fig. 10) that still contains
the major network hubs and key targetable proteins. We also include micro-
environmental inputs (pro-growth & pro-death signals) and phenotypic outputs
(pro-growth & pro-death). Only the internal network assumes recurrent inter-
actions, indicated by double direction arrows in figure 10. The expression of
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Figure 10: Smaller signaling pathway of a melanocyte. The network is
composed of two microenvironmental inputs (pro-growth indicated by white
triangle and pro-death represented by black triangles), 7 internal nodes and two
cell phenotypes (pro-growth and pro-death). White arrows indicate stimulation
or activation, while black arrows represent inhibition or repression.
each protein is modulated by interactions with its neighbors (adjacency matrix,
A and weight matrix, W). We define a prefered network response formalised
into a “goodness function (G)” of the network and use a Monte Carlo algorithm
to obtain W. The algorithm perturbs each element of the weight matrix (W)
and evaluates goodness per iteration. If the perturbed element produces better
goodness, we accept the perturbation, otherwise, we discard the change. We
iterate this process until the value of the goodness function satisfies a given
criteria (see the Appendix for a more detailed discussion of the model).
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Derivation of normal cell weight matrix
In a normal melanocyte, the phenotypic behaviour of the cell (birth or death) is
directly regulated by micro-environmental cues. For a melanocyte that resides
in a growth promoting micro-environment (high pro-growth factor but low pro-
death factors), it is more likely to reproduce (i.e. a higher probability of cell
division). In contrast, a cell living in a growth inhibiting or death promoting
micro-environment, should be less likely to divide and will have a higher chance
of committing apoptosis. To obtain a weight matrix (WN ) that models this
normal cell behavior, we use the goodness function GN , where subscript N
stands for normal.
GN (W ) = |y1 − yn−1|+ |y2 − yn|, (4)
where y1 and y2 are given pro-growth and pro-death microenvironmental in-
puts, respectively. yn−1 is a pro-growth output, and yn is a pro-death output.
The function GN minimizes the difference between input and output. It is
worth noting that we can change the micro-environmental conditions y1,2 to ob-
tain signaling networks that respond to cells under these micro-environmental
changes.
Figure 11: In Silico Gel of a normal melanocyte in different microenvi-
ronments. The protein activity of the pathway is compared in four different
micro-environmental conditions - low-growth & high-death factor, high growth
& high death factor, high growth & low death factor, low growth & low death
factor.
The resulting weight matrix (WN ) produces a profile of the proteins, shown
in figure 11 in four different micro-environmental conditions, i) low growth but
high death, ii) high growth and high death, iii) high growth but low death, and
iv) low growth and low death. Growth factors stimulate the activity of pro-
growth proteins (white nodes in fig. 10: RAS, RAF, PI3K, and ERK), while
pro-death signals increase the activity of pro-death proteins (black nodes in fig.
10: Inhibitor, PTEN, BAD) as we might expect but in mixed environments we
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begin to see more complex dynamics. In micro-environment (i), the expression
of inhibitor is particularly high while all other protein expressions are quite
low. The resulting pro-growth output is quite low (0.3), which means that a
melanocyte in (i) may be less likely to reproduce. In micro-environment (ii),
the expressions of all proteins increase and the pathway produces a higher pro-
growth output (0.5). The expression is even more increased and produces even
higher output (0.6) in condition (iii). Lastly, micro-environment (iv) decreases
protein expression, pushing cells toward an inactive state. The relative changes
in progrowth output that the normal melanocyte displays in different contexts,
gives us some confidence that the network is an appropriate description of a
normal melanocyte. Importantly, these results also highlight the diversity of
protein expression that the same cell can exhibit purely as a result of different
micro-environmental stimulus.
Evolution of melanoma cell lines
In order to generate a collection of melanoma cell lines we mutate our normal
melanocyte network and let it evolve under three different micro-environmental
conditions to simulate different selection pressures. More specifically, we evolve
the normal weight matrix (WN ) derived in the above section, to produce a
weight matrix for melanoma cells. We introduce mutations by changing each
element of the weight matrix (WN ) in a random manner and use the pro-
growth output as a goodness function GM (GM = yn−1), where subscript M
stands for mutation. If a mutated network produces a greater GM value (i.e. it
is more likely to divide), the mutation is accepted. Otherwise, the mutation is
discarded. The weight matrix WN is evolved in three different conditions, i) a
cyclic microenvironment, ii) a pro-death microenvironment (low growth factor &
high death factor), and iii) a pro-growth microenvironment (high growth factor
& low death factor) to generate three different melanoma cell lines. Cell line
1 is evolved in condition (i), cell line 2 in (ii), and cell line 3 is evolved in the
condition (iii).
We compare the typical protein expression of our normal (in silico) melanocyte
and three evolved cell lines (fig. 12) in the high growth factor & low-death fac-
tor (typical in vitro culture conditions) microenvironment. Cell line 1 has a
significantly lower than normal expression of the inhibitor protein (cyan) which
suggests that it may harbour an inactivating mutation. Cell line 2, on the other
hand, may have activating mutations in RAF and ERK as well as an inacti-
vating mutation in PI3K. The expression of cell line 3 is only slightly different
from that of a normal cell. Since cell line 3 was evolved in the grow-promoting
environment, only a slight change in the network was sufficient to satisfy the
given criteria (i.e., high pro-growth output). Due to the complexity of even this
simple network, these cell lines will only truly reveal their full potential when
exposed to many different environments and compared to normal. Of course,
the critical environment that we are most interested in, is drug.
Discussion
In this paper we have reviewed the application of neural networks as models for
the relationship between the micro-environment, genotype, pathway activity
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Figure 12: In Silico Gel of a normal melanocyte and cancerous cell lines. The
protein expression and pro-growth output of a normal melanocyte and three
cancer cell lines (1-3) in microenvironment condition (iii), the high growth factor
& low death factor condition.
and cellular phenotype in tumour cells. Describing all these components simul-
taneously within one model would require a model whose complexity most likely
would render it incomprehensible and hence useless, and and we have therefore
described three separate approaches that focused on different subsystems of the
problem, hence breaking down its complexity to a manageable level.
The neural network methodology has the advantage that it has the capability
of capturing dynamics on two different time scales, that of pathway activity, with
gene activity being influenced by micro-environmental factors and the state of
other genes, and the time scale of evolutionary change, where the expressed
phenotypes are selected for and the respective sublcones might alter the micro-
environment in a feedback loop (see fig. 1). This makes these models suitable
tools for investigating and interrogating the evolutionary dynamics of tumour
growth. However, we do not expect that a single model can encompass all
aspects of this process, but rather that the problem needs to be attacked as
it was presented in this article, in a piecemeal fashion. The first approach we
discussed focused on the feedback between environment and phenotype, the
second case on how the mapping from genotype to phenotype influences drug
efficacy, and the last case investigated the impact of feedback of proteins on
oneanother and how this alters the mapping from environment to phenotype.
The latter approach gave some insight into the architecture of melanocyte
signalling networks, but in terms of identifying the structure of genetic regula-
tory networks, there is a plethora of methods that address this problem with a
high degree of statistical rigour, e.g. dynamic Bayesian networks (48), mutual
information (49) or regularised least squares (50). However, the underlying as-
sumptions about the dynamics of gene regulation are often highly restrictive
(e.g. steady-state, linearisation), and do not lend themselves well to the time-
and context-dependent dynamics of the kind described in the last section. In
a sense it could be said that the neural network approach presents a trade-off
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between network inference and the ability to model the evolutionary dynamics
of the system. As we uncover more details about the rich spatial heterogeneity
in cancer, understanding the role of context in driving selection as well as the
role of the tumour in creating context is becoming increasingly important.
An obvious drawback for the neural network approach is the high level of
abstraction it requires. For example the pathways present in the feed-forward
network in the first section (see fig. 2) do not correspond to any particular path-
ways, but rather represent collections of pathways that influence the respective
output nodes. Of course this can be made more precise, as in last section, where
the expression levels of actual proteins are modelled. Similarly, in section 2 the
mapping from genotype to phenotype is highly non-specific, which, although it
makes the model harder to validate, has the possible advantage that the results
derived from it can be applied to a wide range of different tumour types and
targeted therapies. Naturally the model could also be made more specific and
detailed if a specific type of cancer was to be modelled.
The prospect of going even further and tailoring these models to specific
patients is alluring, especially in the current climate of personalised medicine.
However, before that becomes a reality we need to develop models that are
refined to such a degree that patient data (mutational status, subclone abun-
dance, microenvironmental status etc.) becomes meaningful in the context of
the model. This raises another issue, in the clinic the actual measurements that
are taken from patients largely revolve around single timepoint whole organ
imaging, blood and possibly tissue samples. Making a clinically relevant model
that incorporates even the simplest of the models presented in this review would
mean a paradigm shift in how and what we measure in a patient. This of course
does not mean we should not try to develop the methods before they become
truly translatable.
However, in order to achieve this goal, we do not just need more sophisti-
cated models, but more importantly a closer connection between models and
experiment (and ultimately between experiment and clinic). In terms of the
models discussed here this amounts to a better understanding of how micro-
environmental variables affect both pathway activity and cellular phenotypes.
Quantifying the latter poses a significant challenge, since the phenotypes ob-
served in vivo are often difficult to reproduce and quantify in the lab. This is
starting to change, e.g. with the development of organotypic cultures that rep-
resent a caricature of the real system containing not only cancer cells but also
stromal cells (51, 52, 53) and ex vivo assays (54, 55) that can keep a slice of real
tissue alive for some time. In addition, we also need a better understanding of
the evolutionary pressures affecting tumour growth, and here a careful compar-
ison of model prediction and experimental interrogation can help advance our
knowledge of the complex evolving ecological system that is cancer.
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Appendix
Network parametrisation for agent-based model
In the most basic setting of our model the only input to the network is the
number of neighbours of the cell and the local oxygen concentration. The reason
for this choice is that cancer cells often show weaker response to hypoxia-induced
apoptosis (56) (programmed cell death) and that they tend to adhere less to their
neighbours (57). This implies that the input vector e will have two components,
e = (n(~x, t), c(~x, t)), where n(~x, t) is the number of neighbours and c(~x, t) the
oxygen concentration. The number of neighbours determines if the cell will
proliferate (if n(~x, t) > 3) or become quiescent (if n(~x, t) ≤ 3), while the oxygen
concentration influences the apoptotic response. If the oxygen concentration
falls below a certain threshold cap the apoptosis node is activated and the cell
dies. An initial network that fulfilled the above specifications was created and
used as a ”seed” in every simulation (see fig. 13). For further details we refer
the reader to (32).
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Figure 13: The layout of the initial network used in the agent-based model of
tumour growth. The input to the network is the number of neighbours of the
cell and the local oxygen concentration. The output of the network corresponds
to proliferation (P), quiescence (Q) and apotosis (A), out of which the strongest
is chosen.
Pathway activity in normal and cancer cells
In the pathway model, the activities of proteins in the signaling network are
represented by a vector y ∈ Rn. The first two elements of y represent pro-
growth (y1) and pro-death (y2) inputs and the values are given as external
conditions. We derive the rest of elements by using an adjacent matrix A that
models the connectivity of network and a weight matrix W (Wij ≥ 0) that
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models the strength of each connection (40, 41, 58). The adjacency matrix A
is defined as
Aij =
 1 if an input node j activates an output node i,−1 if an input node j inhibits an output node i,
0 otherwise (no relation).
To obtain a weigth matrix, we use Monte Carlo Algorithm. A weight matrix
is initialized with non-negative random numbers. We use the elementwise prod-
uct of the connectivity matrix A and an weight matrix W to obtain interaction
matrix, V (Vij = Aij ·Wij). The effect of j on i is simply modeled as a product
of the expression level of influence, yjVij . The total influences of the neighbor
of a node i is then the sum of all of its neighbors
Fi =
n∑
j=1
Vijyj , i = 1, 2, ...n (5)
We update the protein activity levels by solving the ordinary differential
equation
dyi
dt
= T
 n∑
j=1
Vijyj
− λyi(t), i = 3, 4, ...n, (6)
where yi(0) = 0, i = 3, 4, ...n and λ is the decay rate of the proteins. The
function T is a transfer function
(
T (x) = 1
1+e−βx
)
. We use this transfer function
to account for saturation effects. The solution of the equation (6), yi is final
protein expression of protein i in the network. Note that y1,2 are given as
microenvironmental (external) conditions and we do not update these nodes
using the above equation.
Next, we use updated protein activity levels to evaluate the pre-defined
goodness function (GN or GM ). We then randomly select an element of weight
matrix and perturb it. We then use equation (5-6) to obtain updated protein
activities. We use these updated levels to evaluate goodness function. We
compare this updated goodness function value to previous one, and accept the
change of the weight element if this new value is closer to pre-defined (desired)
criteira of goodness value. We iterate this process until convergence.
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